General,

You use the term “they” a lot. “They” is the Data Safety Monitoring Board, not Resverlogix, not the clinical steering committee, and not the study site investigators. So yes, the DSMB saw all the unblinded safety and efficacy data. Even if the DSMB could discern efficacy between the placebo and dosed, this data is confidential and cannot be seen by Resverlogix, the clinical steering committee, or the study site investigators.

Just to get the facts straight on the additional compounds……

At the Q1 update, it was stated that “several” follow on molecules have gone through various animal studies for different indications. At Rodman & Renshaw webcast in September, DM stated that they had 7 new follow on molecules and that they will be working with various indications in parallel. Also at R&R he stated “We have already confirmed a 2nd compound, but we have not put it in an IND yet so I didn’t give it a thumbs up”. Now, at the NYC meeting last week, we learned that of these 7 follow on molecules that were alluded to at R&R, that RVX-206, RVX-641, RVX-2101, RVX-2113 just happen to be 4 of DM’s favorites.

BearDownAZ